Lorazepam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lorazepam: From Anxiolytic/Sedative Use to Trigeminal Nerve Neoplasm
One-Sentence Summary
Lorazepam is a benzodiazepine (GABA-A receptor modulator) that is not currently marketed in South Africa, and a formal original-indication record is not available in this evidence pack. The TxGNN model’s top-ranked prediction is Trigeminal Nerve Neoplasm (score 99.87%), but this candidate currently has zero clinical trials and zero published literature, and the evidence pack’s own mechanistic analysis flags it as a likely false-positive knowledge-graph artifact rather than a genuine repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (formal SAHPRA indication text unavailable); internationally established as a sedative/anxiolytic/anticonvulsant (benzodiazepine class) |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.87% (rank 1024) |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed formal mechanism-of-action documentation for lorazepam is not available in this evidence pack. Based on its established pharmacological class, lorazepam is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, producing sedative, anxiolytic, and anticonvulsant effects.
There is no identifiable mechanistic pathway connecting GABA-A receptor modulation to trigeminal nerve neoplasm pathophysiology (tumourigenesis or nerve-sheath tumour biology). The model’s high prediction score most likely reflects a knowledge-graph proximity effect — trigeminal neuralgia and epilepsy frequently co-occur with, or are discussed alongside, trigeminal nerve neoplasm in the underlying knowledge graph — rather than a true causal or therapeutic relationship to lorazepam.
Because no clinical trials, no literature, and no mechanistic rationale support this specific prediction, it should be treated as a hypothesis-generation artifact of the model rather than an evidence-based repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Lorazepam has no SAHPRA product registrations on record and is not currently marketed in South Africa (0 licences found in this evidence pack).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction has no supporting clinical trials, no published literature, and no plausible mechanistic link to trigeminal nerve neoplasm — the evidence pack itself identifies it as a probable knowledge-graph false positive. Combined with the drug’s non-marketed status in South Africa, there is currently no basis to advance this candidate.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings/contraindications) — currently a blocking data gap
- Formal mechanism-of-action data from DrugBank
- Dedicated preclinical/mechanistic evidence linking GABA-A modulation to trigeminal nerve tumour biology, if this hypothesis is to be pursued further
- Note: this evidence pack’s other TxGNN predictions include insomnia (score 99.80%, L2 evidence, “Proceed with Guardrails” recommendation, supported by ~23 clinical trials and ~18 publications) — if the goal is to identify a viable lorazepam repurposing pathway, that candidate warrants a separate, dedicated evaluation report rather than this top-ranked but unsupported prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.